MAOB and Parkinson disease: A secondary analysis of the NET-PD Long-term Study-1 (LS1) (Hauser et al., 2017) identified significant association between longer duration of MAO-B inhibitor exposure (rasagiline monotherapy, N = 586) and less clinical decline, supporting the possibility of slowing clinical disease progression.